Tolerogenic vaccines
Tolerogenic vaccines working principle
  • Share

Different types of allergies have a huge impact on human health worldwide. Adverse drug reactions may affect up to 10% of the world’s population and affect up to 20% of all hospitalized patients; about 9% of toddlers aged 3-5 years have a food allergy; and the rise in prevalence of allergic diseases has continued in the industrialized world for more than 50 years (link).

Selecta Biosciences and Selecta RUS produce and distribute a new class of targeted tolerogenic vaccines based on the tSVP™ platform that helps regulate antigen-specific immune activation or induce antigen-specific immune tolerance. The vaccines are based on the combination of the antigen and immunosuppressor encapsulated in one biodegradable nanoparticle. The tolerogenic effect develops after the simultaneous administration of both agents to dendritic cells that induce the growth of the regulatory T-cells population thus attenuating the immune response for the allergen.

  • Tolerogenic vaccine mechanism of action

Other Selecta Biosciences drug development programs include universal human papillomavirus vaccine, universal influenza vaccine, malaria vaccine, and type 1 diabetes therapeutic vaccine.

Cooperation with RUSNANO

The Visual Science Company has cooperated with the RUSNANO Group since 2008, creating a wide range of high quality graphic information materials. Various infographics have been designed to demonstrate the technologies developed and implemented by RUSNANO project companies. The aim of each project is to demonstrate the principle of technology, nanotechnological components of the project and the advantages of the chosen solution compared with analogues.

The work of Visual Science is carried out in a single sheet or slide format. The modular structure of the infographics makes it possible to use it both as a whole piece or as separate components, which is convenient for preparing website illustrations or project reports or publications. Thus one material helps to solve almost all the issues with illustrating the information about the project.

The target audience for these graphics includes professionals in relevant areas, and a wide range of specialists in different fields without a technical background. Scientific accuracy, combined with the optimum degree of generalization allow for communicating equally effectively with target audiences with different background.

All the graphics have been used by the RUSNANO Group for 5 years or more. As usual, the feature of the Visual Science workflow includes the entire spectrum of tasks ranging from analyzing the scientific literature of the project to the preparation of the final graphics on the company’s side that allows saving valuable time of our customers.

Congratulation for your very succesful 3D HIV model
Prof. Françoise BARRÉ-SINOUSSI
Nobel Prize in Medicine 2008, Pasteur Institute, Paris, France